Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Amarantus Bioscience Holdi AMBS
(Total Views: 613)
Posted On: 05/10/2019 8:53:12 PM
Post# of 30067
Posted By: All Aboard
Re: Mauibound #27764
This is music to my ears. I was really afraid Kitov would give Coeptis the boot for failing to raise funds. Sounds like they still have faith that they can raise money.

“We look forward to the commercial launch in the U.S. by our commercialization partner, Coeptis Pharmaceuticals, which is planned for the fourth quarter of 2019.” stated Kitov CEO, Isaac Israel.

David Mehalick, Co-founder & Executive Vice President of Coeptis, said, “Consensi™ will substantially improve treatment for patients living with two highly prevalent chronic conditions, delivering improved clinical outcomes and enhanced economics for healthcare providers. We expect to have it widely available soon to the millions of Americans who can benefit from this combination treatment.”

The question is whether PsychoGenics will have similar patience or terminate our Eltoprazine license. Boy, a PR update would be helpful ...













(0)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site